Robert Lechleider, serving as the Chief Medical Officer for Immunome Inc. (NASDAQ: IMNM), completed the sale of 55,000 shares of the company's common stock on June 25, 2026. The aggregate value of these transactions reached approximately $1,091,662. The execution of these sales occurred through multiple transactions, with share prices ranging between $19.27 and $21.02 per share. These sales were facilitated under a pre-arranged Rule 10b5-1 trading plan that Lechleider adopted on March 26, 2026.
Before executing the sale, Lechleider acquired the 55,000 shares through the exercise of employee stock options. The exercise price for these options was set at $8.73 per share, resulting in a total cost of $480,150. The options in question carry an expiration date of October 26, 2033. Vesting for these options began with 25% of the shares vesting on October 16, 2024, with the remaining balance vesting on a monthly schedule over the subsequent three years.
Following the completion of these transactions, Lechleider's direct holding of Immunome common stock stands at 15,805 shares. Additionally, he retains an unexercised position of 345,000 employee stock options.
In parallel with the executive transaction, Immunome has reported advancements in its clinical development pipeline. The company has dosed the first patient in a Phase 1 trial evaluating its IM-1617 antibody-drug conjugate for the treatment of solid tumors. This study is designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of the compound.
Furthermore, Immunome presented results from a Phase 3 trial for varegacestat, a therapeutic agent for desmoid tumors, at the American Society of Clinical Oncology Annual Meeting. The data indicated an 84% reduction in the risk of disease progression or death when compared to a placebo. Following these results, the company submitted a New Drug Application to the U.S. Food and Drug Administration for varegacestat.
Market analysts have responded positively to these developments. Truist Securities raised its price target for Immunome to $37, citing the potential market impact of the drug. Additionally, Barclays initiated coverage of Immunome with an overweight rating and established a price target of $36.